{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:23:32Z","timestamp":1769732612050,"version":"3.49.0"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,7,30]],"date-time":"2014-07-30T00:00:00Z","timestamp":1406678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Galderma R&D"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,3]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Once\u2010daily brimonidine tartrate (BT<\/jats:styled-content>) 0.5% gel was shown to provide significantly greater efficacy vs. vehicle for the treatment of facial erythema in patients with rosacea.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To demonstrate that patient satisfaction with overall appearance is correlated with reduction in facial erythema, as measured by clinician and patient assessments.<\/jats:p><\/jats:sec>Methods<\/jats:title>Data from two identical phase III<\/jats:styled-content>, multicentre, randomized, controlled trials of moderate facial erythema of rosacea (study A: n<\/jats:italic>\u00a0=\u00a0260; study B: n<\/jats:italic>\u00a0=\u00a0293) with topical BT<\/jats:styled-content> 0.5% compared to vehicle gel once\u2010daily for 4\u00a0weeks were analysed. Correlations of Patient's Assessment of Appearance (PAA<\/jats:styled-content>) with Clinician's Erythema Assessment (CEA<\/jats:styled-content>) and Patient's Self\u2010Assessment (PSA<\/jats:styled-content>) of erythema were evaluated by calculation of gamma statistics.<\/jats:p><\/jats:sec>Results<\/jats:title>PAA<\/jats:styled-content> correlated with CEA<\/jats:styled-content> post\u2010application on Days 1, 15 and 29 for the intent\u2010to\u2010treat population and provided a median gamma value of 0.57 (min\u00a0=\u00a00.28, max\u00a0=\u00a00.61). PAA<\/jats:styled-content> and PSA<\/jats:styled-content> was also highly correlated post\u2010application on Days 1, 15 and 29; with a median gamma value of 0.87 (min\u00a0=\u00a00.66, max\u00a0=\u00a00.89). Subjects who achieved a clinically meaningful improvement in both CEA<\/jats:styled-content> and PSA<\/jats:styled-content> scales were more likely to report satisfaction with the overall appearance of their skin (P<\/jats:italic>\u00a0<\u00a00.001).<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Both one\u2010 and two\u2010grade improvements in facial erythema assessed by subjects (PSA<\/jats:styled-content>) and clinicians (CEA<\/jats:styled-content>) correlate well with PAA<\/jats:styled-content>, a patient\u2010centered representation of meaningful change.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12587","type":"journal-article","created":{"date-parts":[[2014,7,30]],"date-time":"2014-07-30T05:06:54Z","timestamp":1406696814000},"page":"474-481","source":"Crossref","is-referenced-by-count":13,"title":["Treatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythema"],"prefix":"10.1111","volume":"29","author":[{"given":"J.","family":"Fowler","sequence":"first","affiliation":[{"name":"University of Louisville Louisville KY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tan","sequence":"additional","affiliation":[{"name":"University of Western Ontario and Windsor Clinical Research Inc Windsor ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Jackson","sequence":"additional","affiliation":[{"name":"University of Louisville Louisville KY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Meadows","sequence":"additional","affiliation":[{"name":"The Education & Research Foundation, Inc Lynchburg VA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Jones","sequence":"additional","affiliation":[{"name":"J&S Studies, Inc College Station USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jarratt","sequence":"additional","affiliation":[{"name":"DermResearch, Inc Austin TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Leoni","sequence":"additional","affiliation":[{"name":"Galderma R&D Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.03.030"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120625"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.048"},{"key":"e_1_2_7_5_1","first-page":"43","article-title":"Standard management options for rosacea, part I: overview and broad spectrum of care","volume":"84","author":"Odom R","year":"2009","journal-title":"Cutis"},{"key":"e_1_2_7_6_1","first-page":"435","article-title":"Rosacea: a common, yet commonly overlooked, condition","volume":"66","author":"Blount BW","year":"2002","journal-title":"Am Fam Physician"},{"key":"e_1_2_7_7_1","first-page":"1","article-title":"Systemic therapy for rosacea","volume":"12","author":"Baldwin HE","year":"2007","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_7_8_1","article-title":"Rosacea patients feel effects of their condition in social settings","author":"Drake L","year":"2012","journal-title":"Rosacea Rev"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09894.x"},{"key":"e_1_2_7_10_1","first-page":"73","article-title":"The CLEAR trial: results of a large community\u2010based study of metronidazole gel in rosacea","volume":"79","author":"Wolf JE","year":"2007","journal-title":"Cutis"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.01.048"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10716.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2011.7"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/archderm.1994.01690030091015","article-title":"Rosacea: pathophysiology and treatment","volume":"130","author":"Wilkin JK","year":"1994","journal-title":"Arch Dermatol"},{"key":"e_1_2_7_15_1","first-page":"650","article-title":"Efficacy and safety of once\u2010daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double\u2010blind, vehicle\u2010controlled pivotal studies","volume":"12","author":"Fowler J","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_16_1","first-page":"16","article-title":"Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema","volume":"5","author":"Rosso JQ","year":"2012","journal-title":"Clin Aesthet Dermatol"},{"issue":"3","key":"e_1_2_7_17_1","first-page":"1","article-title":"An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea","volume":"91","author":"Rosso JQ","year":"2013","journal-title":"Cutis"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2011.9"},{"key":"e_1_2_7_19_1","first-page":"1603","article-title":"Helicobacter pylori in patients with rosacea","volume":"89","author":"Rebora A","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000246470"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.02.054"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740331003709736"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2014.04.002"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(96)82030-3"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00286-4"},{"key":"e_1_2_7_26_1","unstructured":"Mirvaso\u00aePrescribing Information. URLhttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204708lbl.pdf(last accessed: 02 June 2014)."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/0471249688"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1740-1445(03)00003-2"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.12"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12587","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12587","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T14:34:16Z","timestamp":1695566056000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,30]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1111\/jdv.12587"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12587","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,30]]}}}